 DecisionBase PDFs --
2008
 Overview:
Diabetic retinopathy is the leading cause of blindness in
working-aged adults in developed nations and is a common complication in type 1
and type 2 diabetics. At present, standard treatment for diabetic retinopathy
is based on nonpharmacological methods. However, drug development efforts for
this indication hold the promise of delivering a variety of novel pharmacological
therapeutics with the potential to improve visual acuity. Indeed, ophthalmologists
indicate that improvement in visual acuity is fast becoming the target outcome
of treatment for diabetic retinopathy, rather than maintenance of visual acuity.
The late-stage pipeline for diabetic retinopathy consists mainly of vascular
endothelial growth factor (VEGF) inhibitors, ophthalmic corticosteroid
implants, and protein kinase C-beta inhibitors. Among the most
promising agents expected to launch during the next ten years are the VEGF
inhibitors.
Questions Answered in This Report:
 Reducing progression of diabetic retinopathy and reducing
vision loss from diabetic retinopathy are key goals in the treatment of diabetic
retinopathy. What are the key primary and secondary clinical trial end points
with which new therapies are evaluated? How do ophthalmologists weight specific
efficacy end points and other drug attributes in their prescribing decisions
for diabetic retinopathy?
Triamcinolone (Bristol-Myers Squibb’s Kenalog; Alcon’s
Triesence) is the 2006 major-market sales leader for diabetic retinopathy. How
will emerging agents fare against triamcinolone? Will emerging therapies offer
improvements in the efficacy end points and drug attributes that are most
influential in physician prescribing decisions? Which emerging therapies, if
any, are best positioned to challenge the market-leading status of triamcinolone?
By 2011, ranibizumab (Genentech/Novartis’s Lucentis) will
emerge as the gold-standard therapy in our drug comparator model because of its improved clinical profile over the current
therapies evaluated in this study. On what clinical attributes is
ranibizumab most differentiated from its competitors? Which current therapies
are at greatest risk of being replaced by ranibizumab?
Scope:
Key drug development opportunity tested in our target
product profiles for diabetic retinopathy: A therapy that is more effective
than bevacizumab in improving visual acuity when used as an adjunct to laser
photocoagulation therapy for the treatment of diabetic retinopathy.
Physicians surveyed for this study: 60 U.S. ophthalmologists.
Comprehensive List of Therapies Included in Our Research and
Modeling
Current therapies:
- Triamcinolone (Bristol-Myers Squibb’s Kenalog;
Alcon’sTriesence)
- Pegaptanib (Pfizer/OSI Eyetech’s Macugen)
- Ranibizumab (Genentech/Novartis’s Lucentis)
- Bevacizumab (Genentech/Roche/Chugai’s Avastin)
Emerging therapies:
- Bevasiranib (Opko Health)
- Aflibercept (Regeneron/Bayer)
- Fluocinolone implant (Alimera/pSivida’s Medidur)
- Dexamethasone implant (Allergan/Sanwa Kagaku Kenkyusho’s
Posurdex)
- Ruboxistaurin (Eli Lilly/Alcon’s Arxxant)
About DecisionBase
Diabetic Retinopathy is a DecisionBase 2008 study from
Decision Resources. DecisionBase 2008 combines market forecasts with clinical
and commercial end points to assess market share projections in 35 indications.
These outputs are driven by quantitative and qualitative primary research.
DecisionBase 2008 provides detailed market share, patient share, and
price-per-day projections for emerging drugs in development. The market share
projections are based on prescriber surveys that compare physicians’
expectations of a potential target product profile with an emerging product
profile of the leading drugs in development.
|
